BAFA – Restoring calcium uptake and preventing osteoporosis
Epicyt Pharma
Epicyt Pharma AB is a Gothenburg-based pharmaceutical R&D company whose development effort is focused on intestinal calcium absorption and how this affects the bone health. The company was founded in 2016 when Lars Fändriks (MD, PhD and Professor in integrative physiology at the Sahlgrenska Academy) and Ville Wallenius (MD, PhD and Associate Professor at the Sahlgrenska Academy) together with a group of investors decided to exploit their discovery research.
First Clinical study completed 2026 with positive outcome
The first clinical study (EPGB001), was completed in March 2026 and showed a positive outcome for BAFA. Patients treated with BAFA increased absorption of calcium significantly and BAFA was well tolerated.
Patent applications are filed for a geographically broad protection of the composition and of the medical use of BAFA. Claims are approved in most regions.
